CAR-T cell as well as preparation method and application thereof

Abstract

The invention discloses a chimeric antigen receptor T (CAR-T) cell as well as a preparation method and application thereof, wherein the CAR of the CAR-T cell comprises a cell membrane exoantigen binding region, a hinge region and an intracellular signal transduction region; the cell membrane exoantigen binding region is chA21scFv for combining with HER2 protein; and the intracellular signal transduction region is CD28-X-ITAM, wherein the X is ICOS, CD137, CD134, CD80 or CD86 costimulatory molecule. The chA21scFv of the CAR-T cell can express anti-HER2 monoclonal antibody, and the HER2 protein is as a target to directly recognize and combine with HER2 protein highly expressed on the surfaces of tumor cells, so that T cells are activated, and cell factors for killing the tumor cells expressing the HER2 protein are secreted.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine

Login to view more

AI Technical Summary

Benefits of technology

This technology allows for targeted delivery or expression of drugs specifically against certain types of cancer-associated growth factor receptors (TrkB) with high levels overexpressed at least two different locations: one inside cell membranes called Trksynaptic density 19 domain 25(trksynapsidy1)and another outside location known as Brain Derived Neurotrophic Factor Receptor 31 (BDNF-1). These proteins are involved in regulating neuronal activity during developmental processes such as embryogenesis and tissue homeostasis. By delivering these agents directly into brain areas affected by those pathways, they could help treat various forms of neuropathies like spinal cord injury caused by nerve root compression syndrome.

Problems solved by technology

This patent describes different ways to use Chimeric Antigens (CAs) technology to create effective treatments against solid malignancies like brain gliomas and other types of melanoid necrotic disease. These techniques involve modifying certain regions within these proteins called domains, allowing them to attach small chemicals onto their surfaces without being restricted from interacting with any type of ligand they may cause harmful side effects when administered systemically due to lack of recognition capabilities at this time. To overcome this problem, researchers developed new methods involving fusion between two fragments containing both DNA segments and another fragment carrying a functional group involved in regulating functions.

Images